Celldex Therapeutics SVP & General Counsel Freddy A. Jimenez Sells 341 Shares for $23.95/Share on 2025-08-13.

Celldex Therapeutics, Inc. (CLDX) announced that Senior Vice President and General Counsel, Freddy A. Jimenez, has executed two transactions on August 13, 2025. Firstly, he sold 341 shares at a price of $23.95 per share, and subsequently, he sold an additional 430 shares at a price of $25.42 per share on the same day.

Celldex Therapeutics Inc. (CLDX), a biotechnology company, reported significant stock transactions executed by Senior Vice President and General Counsel, Freddy A. Jimenez, on August 13, 2025. Jimenez sold a total of 771 shares, consisting of 341 shares at $23.95 per share and an additional 430 shares at $25.42 per share.

These transactions follow a period of financial challenges for Celldex Therapeutics, with the company reporting a net loss of $56.6 million for the second quarter of 2025, a 58% increase from the same period last year. The company's earnings per share (EPS) also deteriorated, with a loss of $0.85 per share compared to $0.54 per share in the second quarter of 2024. Despite the revenue missing analyst estimates by 36%, the company's EPS exceeded expectations by 2.1% [1].

Looking ahead, Celldex Therapeutics expects revenue to grow at an average rate of 71% per annum over the next three years, outpacing the industry average of 19% growth for US biotechs [1]. However, the company's shares have been trading downwards, with a 6.9% decrease from the previous week's closing price.

Jimenez's transactions, while significant, should be considered in the context of the broader market and company performance. The company has one warning sign highlighted by analysts, which investors should be aware of [1]. Additionally, the transactions were executed under the company's 2004 Employee Stock Purchase Plan, indicating a potential long-term investment strategy for the executive [2].

Investors should carefully monitor Celldex Therapeutics' financial performance and the company's ability to meet its growth expectations. The company's stock price volatility and the recent transactions by its executive underscore the need for vigilant monitoring.

References:
[1] https://finance.yahoo.com/news/celldex-therapeutics-second-quarter-2025-121524971.html
[2] https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-ca2cdf727cef.html